Journal
HUMAN GENE THERAPY
Volume 23, Issue 8, Pages 808-815Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2012.140
Keywords
-
Categories
Funding
- National Institutes of Health [NHLBI P01 HL59412-06, 5F32HL095282-03]
- NHLBI Gene Therapy Resource Program
Ask authors/readers for more resources
Lysosomal storage diseases are a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. These diseases are characterized by progressive accumulation of storage material within the lysosomes of affected cells, ultimately leading to cellular dysfunction. Multiple tissues ranging from musculoskeletal and visceral to tissues of the central nervous system are typically involved in disease pathology. Since the advent of enzyme replacement therapy (ERT) to manage some LSDs, general clinical outcomes have significantly improved; however, treatment with infused protein is lifelong and continued disease progression is still evident in patients. Viral gene therapy may provide a viable alternative or adjunctive therapy to current management strategies for LSDs. In this review, we discuss the various viral vector systems that have been developed and some of the strategy designs for the treatment of LSDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available